Instrument Inactif

Autres langues NeoStem Inc Nyse

Actions

NBS

US6406503051

Cours en clôture Nyse Autres places de cotation
- ^USD	-

09/05	Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Lisata Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer	14:30
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results	13/05
Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08/05
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08/05
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02/05
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02/05
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24/04
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	23/04
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	23/04
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	17/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03/04
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	21/03
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues NeoStem Inc Nyse

Actions

NBS

US6406503051

Autres langues

Filtres